Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Cooley

Showing results (61-70 of 87) with videos related to

Pageof 9
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 4, 2012
A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantationNicole A Karras, Matthew Weeres, Wendy Sessions, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 30, 2018
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid LeukemiaTodd A Fehniger, Jeffrey S Miller, Robert K Stuart, et al.
Blood Advances|June 27, 2018
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDSDhifaf Sarhan, Ludwig Brandt, Martin Felices, et al.
Blood|April 11, 2014
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion proteinVeronika Bachanova, Sarah Cooley, Todd E Defor, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 26, 2016
Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host DiseaseDavid A Knorr, Hongbo Wang, Mukta Aurora, et al.
Cytotherapy|September 21, 2010
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancerMelissa A Geller, Sarah Cooley, Patricia L Judson, et al.
Blood|June 29, 2010
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemiaSarah Cooley, Daniel J Weisdorf, Lisbeth A Guethlein, et al.
Blood Advances|July 4, 2019
First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemiaSarah Cooley, Fiona He, Veronika Bachanova, et al.
Brain Imaging and Behavior|April 13, 2015
Regional age differences in gray matter diffusivity among healthy older adultsLauren E Salminen, Thomas E Conturo, David H Laidlaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2016
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced FunctionDaniel A Vallera, Martin Felices, Ron McElmurry, et al.
Pageof 9

Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 4, 2012
A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantationNicole A Karras, Matthew Weeres, Wendy Sessions, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 30, 2018
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid LeukemiaTodd A Fehniger, Jeffrey S Miller, Robert K Stuart, et al.
Blood Advances|June 27, 2018
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDSDhifaf Sarhan, Ludwig Brandt, Martin Felices, et al.
Blood|April 11, 2014
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion proteinVeronika Bachanova, Sarah Cooley, Todd E Defor, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 26, 2016
Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host DiseaseDavid A Knorr, Hongbo Wang, Mukta Aurora, et al.
Cytotherapy|September 21, 2010
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancerMelissa A Geller, Sarah Cooley, Patricia L Judson, et al.
Blood|June 29, 2010
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemiaSarah Cooley, Daniel J Weisdorf, Lisbeth A Guethlein, et al.
Blood Advances|July 4, 2019
First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemiaSarah Cooley, Fiona He, Veronika Bachanova, et al.
Brain Imaging and Behavior|April 13, 2015
Regional age differences in gray matter diffusivity among healthy older adultsLauren E Salminen, Thomas E Conturo, David H Laidlaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2016
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced FunctionDaniel A Vallera, Martin Felices, Ron McElmurry, et al.
Pageof 9